Drug-related adverse events categorized by SOC and PT | Number of patients with grade I/II at > 5% incidence | Number of patients with ≥ grade III |
---|---|---|
Hematological | ||
Neutropenia | 17 (68.0) | 11 (44.0) |
Leukopenia | 11 (44.0) | 2 (8.0) |
Thrombocytopenia | 5 (20.0) | 1 (4.0) |
Lymphocythemia | 3 (12.0) | 2 (8.0) |
Anemia | 3 (12.0) | 0 |
Leukocytosis | 2 (8.0) | 0 |
Non-hematological | ||
Elevated serum lactate dehydrogenase | 11 (44.0) | 1 (4.0) |
Elevated serum α-hydroxybutyrate dehydrogenase | 6 (24.0) | 1 (4.0) |
Hyperuricemia | 5 (20.0) | 3 (12.0) |
Upper respiratory tract infection | 4 (16.0) | 1 (4.0) |
Pneumonia | 4 (16.0) | 4 (16.0) |
Proteinuria | 4 (16.0) | 0 |
Hyperbilirubinemia | 3 (12.0) | 0 |
Elevated alanine aminotransferase | 3 (12.0) | 0 |
Elevated aspartate aminotransferase | 2 (8.0) | 0 |
Elevated serum alkaline phosphatase | 3 (12.0) | 0 |
Weight loss | 3 (12.0) | 0 |
Pneumonitis | 3 (12.0) | 2 (8.0) |
Weight gain | 2 (8.0) | 1 (4.0) |
Elevated γ-glutamyltransferase | 2 (8.0) | 0 |
Elevated bilirubin | 2 (8.0) | 0 |
Diarrhea | 2 (8.0) | 0 |
Cough | 2 (8.0) | 0 |
Oropharyngeal pain | 2 (8.0) | 0 |
Maculopapule | 2 (8.0) | 0 |
Fever | 2 (8.0) | 0 |
Fatigue | 2 (8.0) | 0 |